Protective effect opf lodoxamide tromethamine on allergen inhalation challenge

Area of Science:

• Pharmacology
• Allergy and Immunology
• Respiratory Medicine

Background:

• Mast cell-mediated allergic diseases represent a significant health burden.
• Current prophylactic treatments have limitations.
• Lodoxamide tromethamine is a novel cromolyn-like agent investigated for its anti-allergic properties.

Purpose of the Study:

• To evaluate the efficacy of lodoxamide tromethamine in preventing allergen-induced bronchoconstriction in asthmatic subjects.
• To determine the protective effects of inhaled lodoxamide tromethamine against experimental asthma.

Main Methods:

• A double-blind, placebo-controlled study was conducted.
• Ten allergen-sensitive asthmatic subjects were pretreated with varying doses of lodoxamide tromethamine (0.01, 0.1, or 1.0 mg) or placebo.
• Subjects were subsequently challenged with serial dilutions of allergen extract, and allergen dose-response curves were analyzed.

Main Results:

• Lodoxamide tromethamine pretreatment demonstrated significant protection against allergen-induced bronchoconstriction.
• Even a low dose of 0.01 mg was effective in over 50% of subjects.
• Inhaled administration of 0.1 and 1.0 mg doses uniformly enabled subjects to tolerate higher allergen doses.

Conclusions:

• Lodoxamide tromethamine is an effective prophylactic agent for mast cell-mediated allergic diseases.
• Inhaled lodoxamide tromethamine provides significant protection against experimental allergen-induced bronchoconstriction in asthma.
• The drug exhibits a favorable safety profile with minimal side effects at tested doses.